Cysteinyl 1 Receptor Antagonist Montelukast, Does Not Prevent Peritoneal Membrane Damage in Experimental Chronic Peritoneal Dialysis Model in Rats

Conclusion: This study suggests that montelukast treatment does not prevent the peritoneal membrane from deleterious effects of hyperosmolar PDF in the uremic environment.Kidney Blood Press Res 2014;39:648-657
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research